Creative Bioarray Established Multiple Animal Disease Models to Optimize New Drug Research

(YorkPedia Editorial):- New York City, New York Mar 1, 2023 (Issuewire.com) – Creative Bioarray, the leading biotechnology products and services provider, is founded and managed by a team of leading and experienced experts in the research of biotech and pharmaceutical fields. The relentless pursuit of quality and precision in cell research and innovation are hinged on Creative Biorray’s mission to help customers attain and sustain a healthy life by offering the option of therapies for any possible future treatment of illnesses. Recently, Creative Bioarray announced the release of its multiple animal disease models to optimize new drug research.

Creative Bioarray has established a variety of animal disease models, including cardiovascular disease models, chronic liver disease models, metabolic disease models, nervous system disease models, tumor models, etc. Creative Bioarray provides validated and custom in vivo disease models and services. A comprehensive range of animal-based disease models of different organ systems enables clients to select the most appropriate model to test promising compounds and optimize lead candidates.

Each disease model offered by Creative Bioarray is designed to understand specific aspects of a drug’s properties and its mechanism of action. In addition, animals used for research were provided by certified animal suppliers, and all research protocols and animal use were approved by IACUC.

Animal models are used in various other cancer studies, such as the involvement of environmental factors in tumor formation. Currently, the tumor models offered by Creative Bioarray include cell line-derived xenograft (CDX) models, patient-derived xenograft (PDX) models, syngeneic and orthotopic models, gene-edited animal models, and chemically induced animal models.

Creative Bioarray has successfully developed a variety of cardiovascular models to aid in the development of cardiovascular disease drugs. The application of animal models helps to increase the understanding of cardiovascular diseases and provides new avenues for improving the diagnosis and treatment of diseases. In addition, these models can be used for screening adverse drug reactions, and in vitro and in silico models have recently been proposed to assist in the assessment of cardiotoxicity. Creative Bioarray also provides a variety of CVD models and key technologies to aid in the development of new compounds. In addition, Creative Bioarray can also use cardiovascular models to help design the corresponding optimal plan.

“We typically combine various endpoints to obtain the high-quality and repeatable data our projects require. All experimental models were tested in a dose-dependent manner using approved positive controls.” said Hannah Cole, the marketing director of Creative Bioarray, she also added, “We also have the flexibility and expertise to develop custom in vivo models to meet your specific needs.”

About Creative Bioarray

Creative Bioarray is dedicated to offering customers innovative biotechnology products and services for research use to greatly enhance and drive innovation and standards in science. As a well-recognized industry leader with more than 10 years of experience and in-house expert support, Creative Bioarray has already countenanced research all around the world.

This article was originally published by IssueWire. Read the original article here.